2025
SJR Q2
JCR Q3 · 2,1
OA
10 matched articles
SCIE
Journal detail
Journal of Gastrointestinal Oncology
- Publisher
- AME Publishing Company
- Country
- Hong Kong · Asiatic Region
- Type
- journal
- ISSN
-
207868912219679X
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,659
- Quartile Q2
- H-Index 65
- Cites/doc 1,89
- Docs (3y) 781
- Cites (3y) 1.600
Clarivate
Web of Science · JCR · 2025
- JCR Q Q3
- JIF 2,1
- 5Y JIF 2,3
- JCI 0,46
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Gastroenterology Q2
- Oncology Q3
Areas
- Medicine
WoS categories
- Oncology | Gastroenterology & Hepatology
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q3 | 0,659 | 2,1 | 2,3 | 0,46 | Q3 | 65 |
| 2024 | Q2 | Q3 | 0,687 | 2 | 2,3 | 0,45 | Q3 | 60 |
| 2023 | Q3 | Q3 | 0,6 | 2 | 2,2 | 0,42 | Q3 | 60 |
| 2022 | Q3 | Q4 | 0,606 | 2,1 | 2,5 | 0,42 | Q3 | 60 |
| 2021 | Q2 | Q4 | 0,697 | 2,6 | 2,9 | 0,45 | Q3 | 60 |
| 2020 | Q2 | Q4 | 1,084 | 2,9 | 3,1 | 0,52 | Q3 | 60 |
| 2019 | Q2 | Q3 | 0,928 | 2,5 | — | 0,5 | Q3 | 60 |
| 2017 | Q2 | — | 0,965 | — | — | — | — | 60 |
| 2016 | Q2 | — | 0,85 | — | — | — | — | 60 |
| 2015 | Q2 | — | 0,781 | — | — | — | — | 60 |
| 2014 | Q2 | — | 0,623 | — | — | — | — | 60 |
| 2013 | Q2 | — | 0,662 | — | — | — | — | 60 |
| 2012 | — | — | — | — | — | — | — | 60 |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | GASTROENTEROLOGY & HEPATOLOGY | SCIE | Q3 | Q3 | 101/153 |
| 2025 | ONCOLOGY | SCIE | Q3 | Q3 | 236/333 |
| 2024 | GASTROENTEROLOGY & HEPATOLOGY | SCIE | Q3 | Q3 | 94/148 |
| 2024 | ONCOLOGY | SCIE | Q3 | Q3 | 233/328 |
| 2023 | GASTROENTEROLOGY & HEPATOLOGY | SCIE | Q3 | Q3 | 90/143 |
| 2023 | ONCOLOGY | SCIE | Q3 | Q3 | 222/322 |
| 2022 | GASTROENTEROLOGY & HEPATOLOGY | SCIE | Q4 | Q3 | 78/93 |
| 2022 | ONCOLOGY | SCIE | Q4 | Q3 | 207/241 |
| 2021 | GASTROENTEROLOGY & HEPATOLOGY | SCIE | Q4 | Q3 | 79/93 |
| 2021 | ONCOLOGY | SCIE | Q4 | Q3 | 198/245 |
| 2020 | GASTROENTEROLOGY & HEPATOLOGY | SCIE | Q4 | Q3 | 70/92 |
| 2020 | ONCOLOGY | SCIE | Q4 | Q3 | 191/242 |
| 2019 | GASTROENTEROLOGY & HEPATOLOGY | SCIE | Q3 | Q3 | 62/88 |
| 2019 | ONCOLOGY | SCIE | Q3 | Q3 | 168/244 |